- Trials with a EudraCT protocol (1)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1 result(s) found for: 2019-004566-17.
Displaying page 1 of 1.
| EudraCT Number: 2019-004566-17 | Sponsor Protocol Number: EORTC-1820-CLTF | Start Date*: 2021-07-22 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:European Organisation for Research and Treatment of Cancer | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Cutaneous T-cell lymphoma (Mycosis Fungoides (MF) and Sézary Syndrome (SS)) | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.